Global Assembly Puts Off “Fake” Drug Definition Opposed By India
This article was originally published in PharmAsia News
The World Health Assembly has rejected temporarily a global definition of what constitutes counterfeit drugs, providing relief to Indian generics makers. Indian health activists and the government feared the assembly would adopt a proposed definition that would cover generics as well as fake drugs as part of an effort to reduce the surfeit of counterfeits. The assembly suggested its executive board take a closer look at the International Medical Products Anti-Counterfeiting Taskforce definition opposed by Indian drug makers and their government. Their objection is to the part that determines a medical product counterfeit when "there is a false representation in relation to its identity, history or source, applying to the product, its container, packaging or other labeling information." (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.